Cantor Fitzgerald Reiterates “Overweight” Rating for CG Oncology (NASDAQ:CGON)

CG Oncology (NASDAQ:CGON)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They presently have a $75.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 106.78% from the company’s current price.

A number of other analysts have also issued reports on the stock. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of CG Oncology in a research report on Thursday, April 4th. The Goldman Sachs Group initiated coverage on CG Oncology in a research note on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 target price for the company. Finally, Morgan Stanley initiated coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set an “overweight” rating and a $55.00 target price for the company.

CG Oncology Trading Down 8.2 %

CGON stock traded down $3.23 during trading on Thursday, hitting $36.27. The stock had a trading volume of 2,443,166 shares, compared to its average volume of 390,521. CG Oncology has a 1-year low of $28.55 and a 1-year high of $50.23. The company has a 50 day moving average price of $39.63.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CG Oncology stock. Capstone Investment Advisors LLC acquired a new position in CG Oncology, Inc. (NASDAQ:CGON) during the first quarter, according to the company in its most recent filing with the SEC. The fund acquired 18,354 shares of the company’s stock, valued at approximately $806,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.